Loading…

Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection

Background/Purpose : Interleukin 11 (IL-11) is a multifunctional cytokine derived from bone marrow, which has a trophic effect on small bowel epithelium. This study compares the effects of IL-11 with epidermal growth factor (EGF), a growth factor known to enhance small bowel adaptation. Methods : Fo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pediatric surgery 1998, Vol.33 (1), p.24-29
Main Authors: Fiore, Nicholas F, Ledniczky, George, Liu, Qi, Orazi, Attilio, Du, Xunxiang, Williams, David A, Grosfeld, Jay L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23
cites cdi_FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23
container_end_page 29
container_issue 1
container_start_page 24
container_title Journal of pediatric surgery
container_volume 33
creator Fiore, Nicholas F
Ledniczky, George
Liu, Qi
Orazi, Attilio
Du, Xunxiang
Williams, David A
Grosfeld, Jay L
description Background/Purpose : Interleukin 11 (IL-11) is a multifunctional cytokine derived from bone marrow, which has a trophic effect on small bowel epithelium. This study compares the effects of IL-11 with epidermal growth factor (EGF), a growth factor known to enhance small bowel adaptation. Methods : Forty Sprague-Dawley rats (90 to 100 g) underwent an 85% mid-small bowel resection with primary anastomosis on day 0. Rats were divided into four treatment groups: controls (group I) received bovine serum albumin (BSA), group II received IL-11, 125 μg/kg subcutaneously (SC) twice daily, group III received EGF, 0.10 μg/g SC bid, and group IV received EGF and IL-11 in the above doses. Half of the animals (five per group) were killed on day 4 of therapy, and the rest were killed on day 8. Animals were evaluated for weight, mucosal length, and bowel wall muscle thickness on days 4 and 8, and expression of proliferating cell nuclear antigen (PCNA) in intestinal crypt and smooth muscle cells on day 8. Results : There were two deaths; both were 8-day controls. Body weight was similar at day 4 and day 8. Mucosal thickness in groups II (IL-11) and group IV (IL-11 and EGF) was significantly increased at day 4 and 8 when compared with controls (group 1) and EGF (group III, P < .001). Muscle thickness was significantly increased in the EGF and combined group IV compared with the BSA controls and IL-11 groups ( P < .001). Thirty-two percent of the mucosal crypt cells in Group I stained positive for PCNA, whereas 51%, 53%, and 60% stained positive in groups II (IL-11), III (EGF), and IV (IL-11 and EGF), respectively. In groups I and II, 2% and 1.7% of the myocytes stained positive for PCNA, whereas 11.2% and 5.2% of the myocytes in group III and IV stained positive. Conclusions : These data suggest that IL-11 has a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. EGF has a more generalized effect on intestine causing proliferation of both enterocytes and myocytes. IL-11, with or without EGF, may be a useful adjunct in instances of short bowel syndrome.
doi_str_mv 10.1016/S0022-3468(98)90354-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79687713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022346898903542</els_id><sourcerecordid>79687713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23</originalsourceid><addsrcrecordid>eNqFkM1q3DAURkVJSSbTPsKAFiE0C6f6sS1rVcLQpIFAF0nXQpavErW2NJXsJH37yBkz24JAoO98upeD0IaSS0po_fWeEMYKXtbNF9lcSMKrsmAf0IpWnBYV4eIIrQ7ICTpN6Tch-ZnQY3QsS8GJ5Cv0ug3DTkeXgsfBYudHiD1Mf5wvKMXadxh2roM46B4_xvAyPmGrzRgizoUIyXVTTlKO-_dyGp0HrG3-Bg86JfcMS9qGF-jnCpjRBf8JfbS6T_B5udfo1_X3h-2P4u7nze326q4wvJFjXkJIUwlL2po1wgIpbSs1YZLWjEtrq-yi6qQlsi1tRljbshIaITSpqbCMr9H5_t9dDH-nvJ8aXDLQ99pDmJISss405Rms9qCJIaUIVu2iG3T8pyhRs3H1blzNOpXMZzau5gGbZcDUDtAdWovinJ8tuU5G9zZqb1w6YIw2UkqRsW97DLKMZwdRJePAG-hczMZUF9x_FnkDWpeeIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79687713</pqid></control><display><type>article</type><title>Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Fiore, Nicholas F ; Ledniczky, George ; Liu, Qi ; Orazi, Attilio ; Du, Xunxiang ; Williams, David A ; Grosfeld, Jay L</creator><creatorcontrib>Fiore, Nicholas F ; Ledniczky, George ; Liu, Qi ; Orazi, Attilio ; Du, Xunxiang ; Williams, David A ; Grosfeld, Jay L</creatorcontrib><description>Background/Purpose : Interleukin 11 (IL-11) is a multifunctional cytokine derived from bone marrow, which has a trophic effect on small bowel epithelium. This study compares the effects of IL-11 with epidermal growth factor (EGF), a growth factor known to enhance small bowel adaptation. Methods : Forty Sprague-Dawley rats (90 to 100 g) underwent an 85% mid-small bowel resection with primary anastomosis on day 0. Rats were divided into four treatment groups: controls (group I) received bovine serum albumin (BSA), group II received IL-11, 125 μg/kg subcutaneously (SC) twice daily, group III received EGF, 0.10 μg/g SC bid, and group IV received EGF and IL-11 in the above doses. Half of the animals (five per group) were killed on day 4 of therapy, and the rest were killed on day 8. Animals were evaluated for weight, mucosal length, and bowel wall muscle thickness on days 4 and 8, and expression of proliferating cell nuclear antigen (PCNA) in intestinal crypt and smooth muscle cells on day 8. Results : There were two deaths; both were 8-day controls. Body weight was similar at day 4 and day 8. Mucosal thickness in groups II (IL-11) and group IV (IL-11 and EGF) was significantly increased at day 4 and 8 when compared with controls (group 1) and EGF (group III, P &lt; .001). Muscle thickness was significantly increased in the EGF and combined group IV compared with the BSA controls and IL-11 groups ( P &lt; .001). Thirty-two percent of the mucosal crypt cells in Group I stained positive for PCNA, whereas 51%, 53%, and 60% stained positive in groups II (IL-11), III (EGF), and IV (IL-11 and EGF), respectively. In groups I and II, 2% and 1.7% of the myocytes stained positive for PCNA, whereas 11.2% and 5.2% of the myocytes in group III and IV stained positive. Conclusions : These data suggest that IL-11 has a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. EGF has a more generalized effect on intestine causing proliferation of both enterocytes and myocytes. IL-11, with or without EGF, may be a useful adjunct in instances of short bowel syndrome.</description><identifier>ISSN: 0022-3468</identifier><identifier>EISSN: 1531-5037</identifier><identifier>DOI: 10.1016/S0022-3468(98)90354-2</identifier><identifier>PMID: 9473093</identifier><identifier>CODEN: JPDSA3</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Adaptation, Physiological - drug effects ; Adaptation, Physiological - physiology ; Animals ; Biological and medical sciences ; Cattle ; Cell Division - drug effects ; Epidermal Growth Factor - therapeutic use ; Interleukin-11 - therapeutic use ; Intestinal Mucosa - drug effects ; Intestine, Small - drug effects ; Intestine, Small - surgery ; Male ; Medical sciences ; Rats ; Rats, Sprague-Dawley ; Serum Albumin, Bovine - therapeutic use ; Short Bowel Syndrome - drug therapy ; Short Bowel Syndrome - physiopathology ; Stomach, duodenum, intestine, rectum, anus ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the digestive system ; Time Factors</subject><ispartof>Journal of pediatric surgery, 1998, Vol.33 (1), p.24-29</ispartof><rights>1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23</citedby><cites>FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,4024,4050,4051,23930,23931,25140,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2189997$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9473093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fiore, Nicholas F</creatorcontrib><creatorcontrib>Ledniczky, George</creatorcontrib><creatorcontrib>Liu, Qi</creatorcontrib><creatorcontrib>Orazi, Attilio</creatorcontrib><creatorcontrib>Du, Xunxiang</creatorcontrib><creatorcontrib>Williams, David A</creatorcontrib><creatorcontrib>Grosfeld, Jay L</creatorcontrib><title>Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection</title><title>Journal of pediatric surgery</title><addtitle>J Pediatr Surg</addtitle><description>Background/Purpose : Interleukin 11 (IL-11) is a multifunctional cytokine derived from bone marrow, which has a trophic effect on small bowel epithelium. This study compares the effects of IL-11 with epidermal growth factor (EGF), a growth factor known to enhance small bowel adaptation. Methods : Forty Sprague-Dawley rats (90 to 100 g) underwent an 85% mid-small bowel resection with primary anastomosis on day 0. Rats were divided into four treatment groups: controls (group I) received bovine serum albumin (BSA), group II received IL-11, 125 μg/kg subcutaneously (SC) twice daily, group III received EGF, 0.10 μg/g SC bid, and group IV received EGF and IL-11 in the above doses. Half of the animals (five per group) were killed on day 4 of therapy, and the rest were killed on day 8. Animals were evaluated for weight, mucosal length, and bowel wall muscle thickness on days 4 and 8, and expression of proliferating cell nuclear antigen (PCNA) in intestinal crypt and smooth muscle cells on day 8. Results : There were two deaths; both were 8-day controls. Body weight was similar at day 4 and day 8. Mucosal thickness in groups II (IL-11) and group IV (IL-11 and EGF) was significantly increased at day 4 and 8 when compared with controls (group 1) and EGF (group III, P &lt; .001). Muscle thickness was significantly increased in the EGF and combined group IV compared with the BSA controls and IL-11 groups ( P &lt; .001). Thirty-two percent of the mucosal crypt cells in Group I stained positive for PCNA, whereas 51%, 53%, and 60% stained positive in groups II (IL-11), III (EGF), and IV (IL-11 and EGF), respectively. In groups I and II, 2% and 1.7% of the myocytes stained positive for PCNA, whereas 11.2% and 5.2% of the myocytes in group III and IV stained positive. Conclusions : These data suggest that IL-11 has a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. EGF has a more generalized effect on intestine causing proliferation of both enterocytes and myocytes. IL-11, with or without EGF, may be a useful adjunct in instances of short bowel syndrome.</description><subject>Adaptation, Physiological - drug effects</subject><subject>Adaptation, Physiological - physiology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cattle</subject><subject>Cell Division - drug effects</subject><subject>Epidermal Growth Factor - therapeutic use</subject><subject>Interleukin-11 - therapeutic use</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestine, Small - drug effects</subject><subject>Intestine, Small - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Serum Albumin, Bovine - therapeutic use</subject><subject>Short Bowel Syndrome - drug therapy</subject><subject>Short Bowel Syndrome - physiopathology</subject><subject>Stomach, duodenum, intestine, rectum, anus</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the digestive system</subject><subject>Time Factors</subject><issn>0022-3468</issn><issn>1531-5037</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkM1q3DAURkVJSSbTPsKAFiE0C6f6sS1rVcLQpIFAF0nXQpavErW2NJXsJH37yBkz24JAoO98upeD0IaSS0po_fWeEMYKXtbNF9lcSMKrsmAf0IpWnBYV4eIIrQ7ICTpN6Tch-ZnQY3QsS8GJ5Cv0ug3DTkeXgsfBYudHiD1Mf5wvKMXadxh2roM46B4_xvAyPmGrzRgizoUIyXVTTlKO-_dyGp0HrG3-Bg86JfcMS9qGF-jnCpjRBf8JfbS6T_B5udfo1_X3h-2P4u7nze326q4wvJFjXkJIUwlL2po1wgIpbSs1YZLWjEtrq-yi6qQlsi1tRljbshIaITSpqbCMr9H5_t9dDH-nvJ8aXDLQ99pDmJISss405Rms9qCJIaUIVu2iG3T8pyhRs3H1blzNOpXMZzau5gGbZcDUDtAdWovinJ8tuU5G9zZqb1w6YIw2UkqRsW97DLKMZwdRJePAG-hczMZUF9x_FnkDWpeeIw</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Fiore, Nicholas F</creator><creator>Ledniczky, George</creator><creator>Liu, Qi</creator><creator>Orazi, Attilio</creator><creator>Du, Xunxiang</creator><creator>Williams, David A</creator><creator>Grosfeld, Jay L</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection</title><author>Fiore, Nicholas F ; Ledniczky, George ; Liu, Qi ; Orazi, Attilio ; Du, Xunxiang ; Williams, David A ; Grosfeld, Jay L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adaptation, Physiological - drug effects</topic><topic>Adaptation, Physiological - physiology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cattle</topic><topic>Cell Division - drug effects</topic><topic>Epidermal Growth Factor - therapeutic use</topic><topic>Interleukin-11 - therapeutic use</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestine, Small - drug effects</topic><topic>Intestine, Small - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Serum Albumin, Bovine - therapeutic use</topic><topic>Short Bowel Syndrome - drug therapy</topic><topic>Short Bowel Syndrome - physiopathology</topic><topic>Stomach, duodenum, intestine, rectum, anus</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the digestive system</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiore, Nicholas F</creatorcontrib><creatorcontrib>Ledniczky, George</creatorcontrib><creatorcontrib>Liu, Qi</creatorcontrib><creatorcontrib>Orazi, Attilio</creatorcontrib><creatorcontrib>Du, Xunxiang</creatorcontrib><creatorcontrib>Williams, David A</creatorcontrib><creatorcontrib>Grosfeld, Jay L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiore, Nicholas F</au><au>Ledniczky, George</au><au>Liu, Qi</au><au>Orazi, Attilio</au><au>Du, Xunxiang</au><au>Williams, David A</au><au>Grosfeld, Jay L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection</atitle><jtitle>Journal of pediatric surgery</jtitle><addtitle>J Pediatr Surg</addtitle><date>1998</date><risdate>1998</risdate><volume>33</volume><issue>1</issue><spage>24</spage><epage>29</epage><pages>24-29</pages><issn>0022-3468</issn><eissn>1531-5037</eissn><coden>JPDSA3</coden><abstract>Background/Purpose : Interleukin 11 (IL-11) is a multifunctional cytokine derived from bone marrow, which has a trophic effect on small bowel epithelium. This study compares the effects of IL-11 with epidermal growth factor (EGF), a growth factor known to enhance small bowel adaptation. Methods : Forty Sprague-Dawley rats (90 to 100 g) underwent an 85% mid-small bowel resection with primary anastomosis on day 0. Rats were divided into four treatment groups: controls (group I) received bovine serum albumin (BSA), group II received IL-11, 125 μg/kg subcutaneously (SC) twice daily, group III received EGF, 0.10 μg/g SC bid, and group IV received EGF and IL-11 in the above doses. Half of the animals (five per group) were killed on day 4 of therapy, and the rest were killed on day 8. Animals were evaluated for weight, mucosal length, and bowel wall muscle thickness on days 4 and 8, and expression of proliferating cell nuclear antigen (PCNA) in intestinal crypt and smooth muscle cells on day 8. Results : There were two deaths; both were 8-day controls. Body weight was similar at day 4 and day 8. Mucosal thickness in groups II (IL-11) and group IV (IL-11 and EGF) was significantly increased at day 4 and 8 when compared with controls (group 1) and EGF (group III, P &lt; .001). Muscle thickness was significantly increased in the EGF and combined group IV compared with the BSA controls and IL-11 groups ( P &lt; .001). Thirty-two percent of the mucosal crypt cells in Group I stained positive for PCNA, whereas 51%, 53%, and 60% stained positive in groups II (IL-11), III (EGF), and IV (IL-11 and EGF), respectively. In groups I and II, 2% and 1.7% of the myocytes stained positive for PCNA, whereas 11.2% and 5.2% of the myocytes in group III and IV stained positive. Conclusions : These data suggest that IL-11 has a trophic effect on small intestinal enterocytes, causing cell proliferation and increased mucosal thickness. EGF has a more generalized effect on intestine causing proliferation of both enterocytes and myocytes. IL-11, with or without EGF, may be a useful adjunct in instances of short bowel syndrome.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>9473093</pmid><doi>10.1016/S0022-3468(98)90354-2</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3468
ispartof Journal of pediatric surgery, 1998, Vol.33 (1), p.24-29
issn 0022-3468
1531-5037
language eng
recordid cdi_proquest_miscellaneous_79687713
source ScienceDirect Freedom Collection 2022-2024
subjects Adaptation, Physiological - drug effects
Adaptation, Physiological - physiology
Animals
Biological and medical sciences
Cattle
Cell Division - drug effects
Epidermal Growth Factor - therapeutic use
Interleukin-11 - therapeutic use
Intestinal Mucosa - drug effects
Intestine, Small - drug effects
Intestine, Small - surgery
Male
Medical sciences
Rats
Rats, Sprague-Dawley
Serum Albumin, Bovine - therapeutic use
Short Bowel Syndrome - drug therapy
Short Bowel Syndrome - physiopathology
Stomach, duodenum, intestine, rectum, anus
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
Time Factors
title Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A41%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20interleukin-11%20and%20epidermal%20growth%20factor%20on%20residual%20small%20intestine%20after%20massive%20small%20bowel%20resection&rft.jtitle=Journal%20of%20pediatric%20surgery&rft.au=Fiore,%20Nicholas%20F&rft.date=1998&rft.volume=33&rft.issue=1&rft.spage=24&rft.epage=29&rft.pages=24-29&rft.issn=0022-3468&rft.eissn=1531-5037&rft.coden=JPDSA3&rft_id=info:doi/10.1016/S0022-3468(98)90354-2&rft_dat=%3Cproquest_cross%3E79687713%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-1179c57f0b6287fe04fb9a02916239ff51015d9f09b4f6282bb24e877a0617f23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79687713&rft_id=info:pmid/9473093&rfr_iscdi=true